# Lanthanum carbonate

## Fosrenol Chewable 750mg

| 藥物代碼           | OFOSR                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Reduction of serum phosphate in patients with stage 5 chronic kidney disease (end-stage renal disease ; kidney failure: GFR <15 mL/minute/1.73 m2 or dialysis)                                                                                                                                                                                                                                                                                                  |
| 副作用             | Nausea, headache, Vomiting, abdominal pain, Allergic skin reactions, bowel obstruction, constipation, dyspepsia, fecal impaction, hypophosphatemia, ileus                                                                                                                                                                                                                                                                                                       |
| 禁忌               | Bowel obstruction, fecal impaction, ileus, Hypersensitivity to lanthanum carbonate or any component of the formulation; hypophosphatemia                                                                                                                                                                                                                                                                                                                        |
| 藥物保存方式       | 室溫                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 用法用量           | End stage renal disease - Hyperphosphatemia a) Initial dose: 1500 mg per day in divided doses with meals, then titrate in increments of 750 mg/day at intervals of 2 to 3 weeks until an acceptable serum phosphate level is reached b) Maintenance dose: 1500 to 3000 mg per day in divided doses with meals is usually required to achieve plasma phosphate levels less than 6 mg/dL c) Maximum dose: Doses up to 4500 mg/day were evaluated in ESRD patients |
| 肝功能異常         | 無需調整劑量  需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 腎功能異常         | 無需調整劑量  需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 懷孕用藥危分級     | 除非治療上需要                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 孕期用藥建議       | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 哺乳期用藥建議     | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                             |
| 附帶說明           | upper table (according to up to date of Pregnancy Risk Factor and Lactation )                                                                                                                                                                                                                                                                                                                                                                                   |
| 注射劑給藥建議途徑 | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

